HCG Beta Total Quantitative, Tumor Marker - Book Test at Low Cost

Why Tested?

To asset diagnosed  and monitored gestational trophoblastic malady or Germ cell tumors

When to Get Tested?

When your manifestation implies gestational trophoblastic ailment or germ compartment tumors; evaluate the persuasiveness of antidote for these conditions; to scrutinize for repetition.

Specimen Required

Patient Preparation

AMASS

Serum partition tube. Also satisfactory: Lavender (K2EDTA or K3EDTA), pink (K2EDTA), or leafy (lithium heparin).

Specimen Preparation

Entitle the representative to clot entirely at room temperature. Detach serum from enclosures ASAP or within 2 hours of assemblage. Transfer 1 mL of serum to the tube.

Storage/Transportation Temperatures

Refrigerated.

Inappropriate Conditions

Specimens left to coagulate at 2-8.00°C or specimens subjected to repeatedly freeze-dried/thawed rotations.

Resilience

After that alienation from partitions: Ambient: five days and; Refrigerated:  two weeks; Frozen:one  year

Consideration Interval

Men : 0-3 IU/L

Women: 0-5 IU/L

When is HCG Monitoring Specifically Recommended?

According to clinical practice guidelines from numerous medical associations, the use of hCG as a tumor marker is limited to a few specific settings. These guidelines recommend it in the workup and monitoring of patients with suspected or known germ cell tumors of the testes and patients with GTD.

However, there is less consensus about using hCG in patients with germ cell tumors of the ovary, as ovarian cancer monitoring is more commonly performed using the tumor marker CA-125. The European Group on Tumor Markers as well as AACC Academy do not recommend the routine use of hCG for ovarian tumors, while the National Comprehensive Cancer Network states that hCG can be measured to assess less common ovarian histopathologies.

Results

β-hCG exhibited no reliable source of diagnostic values in ovarian cancers. A discrepancy between serum and distinct FIGO phases was noted, but nothing between β-hCG levels and diverse histological parties of tumors. There were 10.20% false positives and 18.90% of inaccurate negative impact results in all measures.

Culmination

The service of β-hCG as a tumor marker for ovarian cancers is justified only in patients with preoperatively higher grades in advanced technology FIGO scenes (III and IV), regardless of the histological type of tumor.